Compare AKBA & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKBA | EQBK |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 870.8M |
| IPO Year | 2014 | 2015 |
| Metric | AKBA | EQBK |
|---|---|---|
| Price | $1.42 | $47.28 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $5.92 | ★ $50.50 |
| AVG Volume (30 Days) | ★ 3.1M | 90.7K |
| Earning Date | 03-12-2026 | 01-21-2026 |
| Dividend Yield | N/A | ★ 1.52% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.23 |
| Revenue | ★ $225,071,000.00 | $199,739,000.00 |
| Revenue This Year | $52.41 | $76.83 |
| Revenue Next Year | $21.57 | $4.61 |
| P/E Ratio | ★ N/A | $38.61 |
| Revenue Growth | ★ 32.49 | N/A |
| 52 Week Low | $1.30 | $34.11 |
| 52 Week High | $4.08 | $50.07 |
| Indicator | AKBA | EQBK |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 57.82 |
| Support Level | $1.35 | $46.80 |
| Resistance Level | $1.44 | $48.25 |
| Average True Range (ATR) | 0.08 | 1.55 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 42.50 | 54.28 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.